Skip to content

MDMA for PTSD

Studies whose primary subject is both MDMA and PTSD, with an evidence synthesis read across the most-cited and most recent of them.

State of the evidence

Synthesized

Synthesized from 22 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for MDMA, ecstasy, molly, methylenedioxymethamphetamine, PTSD, post-traumatic stress disorder, then ranked by relevance.

Across randomized trials, MDMA-assisted therapy reduces PTSD symptoms substantially more than placebo with therapy, with large effects on clinician-rated symptom severity (roughly 10-point greater CAPS reductions in phase 3 trials) and smaller but consistent gains in functional impairment; meta-analyses support greater likelihood of clinically meaningful improvement and loss of diagnosis. Benefits appear durable in long-term follow-up, though samples are small. The main caveats are small trial sizes, difficulty blinding participants to a psychoactive drug, non-standardized therapy, a common sponsor across trials, and ethical/regulatory concerns.

Evidence by study

Direction is which way each study's own result points, not our rating of the study. All 23 matching studies were reviewed; the 22 that directly address the question are shown here.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. 2021 RCT 90 Supports MDMA-assisted therapy produced significantly greater CAPS-5 reductions than placebo (d = 0.91) and greater functional improvement (d = 0.43), with no serious adverse events.
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. 2010 RCT 20 Supports MDMA-assisted psychotherapy reduced CAPS scores significantly more than placebo at all post-baseline time points, with 83% versus 25% clinical response and no drug-related serious adverse events.
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. 2018 RCT (dose-response) 26 Supports Active MDMA doses (75 and 125 mg) produced larger CAPS-IV reductions than a 30 mg control at one month, and reductions persisted at 12 months after open-label dosing.
A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD) 2012 RCT 12 Mixed Full-dose MDMA-assisted psychotherapy produced significant self-reported symptom improvement but clinician-rated CAPS reductions did not reach significance (p = 0.066), with further improvement at one year.
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. 2023 RCT 104 Supports MDMA-assisted therapy reduced CAPS-5 scores more than placebo with therapy (d = 0.7) and improved functional impairment (d = 0.4), with no deaths or serious treatment-emergent adverse events.
Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. 2013 long-term follow-up 19 Supports Gains in symptom relief were maintained over a mean of 45 months after MDMA-assisted psychotherapy, with no evidence of harm or drug dependency, though two participants relapsed.
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. 2016 review Supports Describes MDMA as showing encouraging results as an adjunct to psychotherapy for refractory PTSD, while calling for further research.
3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. 2018 RCT (dose-response) 28 Supports Active MDMA doses produced larger CAPS reductions than a 40 mg low dose, reaching significance only in the per-protocol set, and 76% no longer met PTSD criteria at 12 months.
MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? 2018 review Supports Argues that MDMA-assisted psychotherapy may work through memory reconsolidation and fear extinction via monoamine, oxytocin, and cortisol effects on emotional memory circuits, citing durable remission in 68% of phase 2 participants.
MDMA-Assisted Psychotherapy Using Low Doses in a Small Sample of Women with Chronic Posttraumatic Stress Disorder 2008 observational cohort 6 Supports Low doses of MDMA (50-75 mg) were psychologically and physiologically safe in all six women, with preliminary efficacy data; the study was closed early.
Clinical applications of hallucinogens: A review. 2016 review Supports Argues that a growing body of evidence indicates hallucinogens, including entactogens such as MDMA, may have therapeutic applications beyond their potential for abuse.
MDMA‐Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta‐Analysis 2021 systematic review with meta-analysis Supports MDMA-assisted psychotherapy reduced CAPS scores more than control therapy (mean difference -22.03) with high heterogeneity, and increased rates of clinically significant improvement (RR 3.65) and loss of PTSD diagnosis (RR 2.10).
Registered clinical studies investigating psychedelic drugs for psychiatric disorders. 2021 review of registered trials 70 Unclear Reports that most registered psychedelic trials study MDMA or psilocybin for PTSD and depression, but only 21 of 70 had published results.
[The use of psychedelics in psychiatry]. 2026 review Mixed Argues that MDMA-assisted psychotherapy has the largest phase 3 dataset in PTSD but was declined FDA approval in 2024 on ethical grounds, and that certainty of evidence remains low or very low.
A Systematic Review of MDMA’s Effects on Social Cognition in Placebo-Controlled Trials 2026 systematic review Mixed Across 75 placebo-controlled studies, MDMA consistently enhanced subjective social experience but behavioral prosociality was inconsistent, and it reduced accuracy in identifying negative social cues.
MDMA-Assisted Therapy May Decrease PTSD Symptoms, Dissociation, Depression, and Functional Disability: A Systematic Review and Meta-Analysis 2026 systematic review and meta-analysis Supports Across seven RCTs, MDMA-assisted psychotherapy may significantly improve PTSD symptoms, dissociation, depression, and functional impairment but not sleep quality, with limitations from small samples, blinding challenges, non-standardized therapy, and a common sponsor.
Healing together: Results from a pilot trial of 3,4-Methylenedioxymethamphetamine-enhanced cognitive-behavioral conjoint therapy for posttraumatic stress disorder. 2026 pilot trial Supports MDMA-enhanced cognitive-behavioral conjoint therapy was feasible and acceptable and was associated with clinically meaningful PTSD symptom reductions and improved relationship satisfaction.
717. Clinical trials, ethical dimensions, and the pathway of MDMA-assisted therapy in PTSD 2026 literature review Unclear Argues that MDMA-assisted therapy trials raise distinctive ethical issues around patient vulnerability, memory and belief changes, and informed consent, requiring systematic attention to consent, therapist training, and risk monitoring.
MDMA-Enhanced Exposure Therapy Reverses PTSD-Like Features In a Learned Helplessness Mouse Model 2026 preclinical study Supports MDMA combined with trauma-cue exposure produced rapid and sustained recovery in trauma-susceptible mice, with dose-dependent effects on anxiety- and depression-related measures.
The occurrence and potential role of mystical experiences in MDMA-assisted therapy for PTSD: A secondary analysis 2026 secondary analysis of two RCTs 53 Mixed MDMA sessions produced higher mystical-experience scores than placebo, and only the Positive Mood subscale significantly mediated PTSD symptom reduction.
Prevalence of Potential Contraindications and Risk Factors Relevant to MDMA-Assisted Therapy Among U.S. Veterans with Posttraumatic Stress Disorder 2026 serial cross-sectional study Unclear Each year 15.3-17.3% of veterans with PTSD had at least one contraindication for MDMA-assisted therapy, 55.2-58.2% had a conditional or modifiable risk factor, and 85.7-87.5% filled a prescription for a potentially interacting medication.
MDMA as an early post-trauma intervention in a translational animal model of PTSD. 2026 controlled animal study 175 Supports MDMA at 10 mg/kg given 30 minutes after stress or 24 hours later with trauma-cue pairing reduced anxiety-like behavior, startle, and freezing, while lower doses and unpaired delayed administration were ineffective.

Points of agreement

  • Multiple randomized trials and meta-analyses find MDMA-assisted therapy reduces clinician-rated PTSD symptoms more than placebo or low-dose control with therapy.
  • Functional impairment improves alongside symptoms, though with smaller effect sizes than symptom severity.
  • Clinical response and loss of PTSD diagnosis are more frequent with MDMA-assisted therapy.
  • Serious adverse events are uncommon in trials; commonly reported effects include anxiety, jitteriness, headache, nausea, and bruxism.
  • Long-term follow-up and 12-month assessments suggest gains are often maintained, though some participants relapse.
  • Animal work supports a mechanistic rationale involving fear extinction and memory reconsolidation.

Conflicts

  • One small pilot found clinician-rated CAPS reductions did not reach significance while self-report improved, whereas larger trials report significant clinician-rated effects.
  • One dose-response trial reached significance only in the per-protocol set, not the intent-to-treat set.
  • Meta-analyses report high statistical heterogeneity for symptom-severity effects.
  • One review characterizes overall certainty of evidence as low or very low and notes FDA declined approval on ethical grounds, contrasting with the positive efficacy findings.

Gaps

  • Blinding is difficult with a psychoactive drug, and functional unblinding may inflate effects.
  • Several trials are small, and a common sponsor across trials limits independence.
  • Therapy protocols are not standardized across studies.
  • Durability data come from small follow-up samples with some relapse.
  • Little evidence on which patients are unsuitable, given high rates of contraindications and interacting medications among veterans.
  • Ethical and consent issues in vulnerable patients are discussed but not empirically studied.
Browse these studies in the library

Common questions

What does the research agree on about MDMA for PTSD?
  • Multiple randomized trials and meta-analyses find MDMA-assisted therapy reduces clinician-rated PTSD symptoms more than placebo or low-dose control with therapy.
  • Functional impairment improves alongside symptoms, though with smaller effect sizes than symptom severity.
  • Clinical response and loss of PTSD diagnosis are more frequent with MDMA-assisted therapy.
  • Serious adverse events are uncommon in trials; commonly reported effects include anxiety, jitteriness, headache, nausea, and bruxism.
  • Long-term follow-up and 12-month assessments suggest gains are often maintained, though some participants relapse.
  • Animal work supports a mechanistic rationale involving fear extinction and memory reconsolidation.
Where do studies on MDMA for PTSD conflict?
  • One small pilot found clinician-rated CAPS reductions did not reach significance while self-report improved, whereas larger trials report significant clinician-rated effects.
  • One dose-response trial reached significance only in the per-protocol set, not the intent-to-treat set.
  • Meta-analyses report high statistical heterogeneity for symptom-severity effects.
  • One review characterizes overall certainty of evidence as low or very low and notes FDA declined approval on ethical grounds, contrasting with the positive efficacy findings.
What is still unknown about MDMA for PTSD?
  • Blinding is difficult with a psychoactive drug, and functional unblinding may inflate effects.
  • Several trials are small, and a common sponsor across trials limits independence.
  • Therapy protocols are not standardized across studies.
  • Durability data come from small follow-up samples with some relapse.
  • Little evidence on which patients are unsuitable, given high rates of contraindications and interacting medications among veterans.
  • Ethical and consent issues in vulnerable patients are discussed but not empirically studied.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is MDMA for PTSD, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when MDMA for PTSD or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

204 articles · 60 from the last two years · 8,353 participants across 74 studies reporting sample size

Common study designs

review 49 systematic review 10 randomized controlled trial 18 theoretical or philosophical paper 16 systematic review and meta-analysis 8

Research volume by year

Compare topics →

200 studies whose primary subject is MDMA for PTSD since 2002

Studies about MDMA for PTSD per year, 2002 to 2026, peaking at 30 in 2024 Bar chart: one bar per year, taller where more studies were published that year. 0 15 30 2005 2010 2015 2020 2025
2026 is partial
Show the numbers
Studies about MDMA for PTSD per year, 2002 to 2026, peaking at 30 in 2024
Year Studies
2002 1
2003 0
2004 0
2005 0
2006 0
2007 0
2008 1
2009 0
2010 2
2011 1
2012 1
2013 1
2014 2
2015 1
2016 6
2017 3
2018 12
2019 6
2020 9
2021 19
2022 25
2023 23
2024 30
2025 28
2026 29

Research

Synthesize the evidence →

MDMA-Assisted Therapy for Veterans with Comorbid Posttraumatic Stress Disorder and Alcohol Use Disorder: Clinical Outcomes from the First Open-Label Pilot Trial.

Alcohol October 30, 2026 Erica Eaton, Christy Capone, Brian J Gully et al.

Co-occurring posttraumatic stress disorder and alcohol use disorder (PTSD-AUD) are highly prevalent among U.S. Veterans and associated with greater symptom severity, functional impairment, and poorer outcomes than either disorder alone. Existing treatments demonstrate modest effectiveness, with persistent challenges in engagement, retention, and sustained improvement. To evaluate the...

DOI: 10.1016/j.alcohol.2026.107464 (opens in new tab) Full text (opens in new tab) Alcohol use disorder Comorbidity MDMA-Assisted Therapy Posttraumatic stress disorder +1

Adapted Massed Exposure Therapy Enhanced with MDMA for PTSD (aMETEMP): A randomized, double-masked protocol adapted for Veterans Affairs healthcare system

Contemporary Clinical Trials Communications October 27, 2026 Leslie A. Morland, Bettye E Chargin, Barbara Olasov Rothbaum et al.

Posttraumatic stress disorder (PTSD) remains prevalent and disabling, especially among veterans, with a substantial proportion failing to achieve remission following first-line evidence-based trauma-focused psychotherapies. 3,4-Methylenedioxymethamphetamine (MDMA) is hypothesized to enhance psychotherapy outcomes through effects on fear extinction, cognitive flexibility, and emotional...

DOI: 10.1016/j.conctc.2026.101705 (opens in new tab)

The Nova Protocol: a comprehensive multimodal longitudinal study among civilian survivors of a mass trauma event.

European Journal of Psychotraumatology September 14, 2026 Roee Admon, Ophir Netzer, Noa Magal et al.

Background: The 7 October 2023 attack in southern Israel was one of the deadliest terror attacks in modern history, with 1,182 fatalities, more than 4,000 wounded individuals, and 251 hostages. The Nova music festival, an all-night outdoor rave near the Gaza border, suffered the highest number of civilian casualties, with more than 370 festival attendees killed. Survivors were exposed to...

DOI: 10.1080/20008066.2026.2721729 (opens in new tab) Full text (opens in new tab) MDMA PTSD Tept Ecological assessment +10

[The use of psychedelics in psychiatry].

Orvosi hetilap September 13, 2026 Szabolcs Kéri

Over the past five years, the literature on the psychiatric use of psychedelic and related treatments has expanded substantially. Several randomized controlled trials and pooled analyses have been conducted in mood disorders, treatment-resistant depression, and post-traumatic stress disorder. Trial methodology, however, remains a fundamental source of uncertainty, and despite the popularity of...

DOI: 10.1556/650.2026.33665 (opens in new tab) Full text (opens in new tab) MDMA Post-traumatic stress disorder Psilocybin Treatment-resistant depression +7

A Systematic Review of MDMA’s Effects on Social Cognition in Placebo-Controlled Trials

PsyArXiv Preprints September 11, 2026 preprint

Background 3,4-Methylenedioxymethamphetamine (MDMA) is associated with distinctive prosocial and empathogenic effects, yet the consistency and scope of its impact on social cognition in humans remain unclear. Although numerous placebo-controlled studies have examined MDMA’s acute social effects, findings vary widely across subjective and behavioural domains. Methods We conducted a systematic...

DOI: osf:sgdau_v3 (opens in new tab) Full text (opens in new tab) MDMA PTSD 3 4-methylenedioxymethamphetamine Empathy +12

MDMA-Assisted Therapy May Decrease PTSD Symptoms, Dissociation, Depression, and Functional Disability: A Systematic Review and Meta-Analysis

Harvard Review of Psychiatry September 8, 2026 Warwick M. Green, Sanket B Raut, F. E. James et al.

There is a need for new effective treatment options for posttraumatic stress disorder (PTSD), as many people with PTSD do not fully recover despite current treatments. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AT) is emerging as a new treatment option. We assessed the current body of MDMA-AT evidence for effectiveness in treating PTSD, associated impairments, and...

DOI: 10.1097/hrp.0000000000000478 (opens in new tab)

717. Clinical trials, ethical dimensions, and the pathway of MDMA-assisted therapy in PTSD

The International Journal of Neuropsychopharmacology September 1, 2026 Christopher Poppe, Dimitris Repantis

Abstract Background MDMA-assisted therapy (MDMA-AT) has shown promise for treatment-resistant post-traumatic stress disorder (PTSD), leveraging unique affective effects such as enhanced trust, empathy, and social connectedness. Despite preliminary efficacy, ethical challenges in clinical trials may directly affect regulatory approval and future clinical implementation. Aims & Objectives The...

DOI: 10.1093/ijnp/pyag040.489 (opens in new tab)

MDMA-Enhanced Exposure Therapy Reverses PTSD-Like Features In a Learned Helplessness Mouse Model

bioRxiv (Cold Spring Harbor Laboratory) August 12, 2026 Orr Shahar, Perettz Golding, Masha Chaykin et al. preprint

Abstract Post-traumatic stress disorder (PTSD) is a highly prevalent, debilitating psychiatric condition. Existing treatments are ineffective for many patients. 3,4- methylenedioxymethamphetamine (MDMA)-assisted psychotherapy has demonstrated substantial clinical efficacy but relies on prolonged, resource-intensive therapeutic protocols that limit scalability and accessibility. Here, we...

DOI: 10.64898/2026.08.06.743271 (opens in new tab) Full text (opens in new tab)

The occurrence and potential role of mystical experiences in MDMA-assisted therapy for PTSD: A secondary analysis

Journal of Psychopharmacology August 6, 2026 Tijmen Bostoen, Erwin Krediet, Annette van Schagen et al.

Background: The potential safety and efficacy of the psychedelic 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) has been researched in phase 2 and phase 3 clinical trials. We examined the occurrence and role of mystical experiences in MDMA-AT. Methods: Data were sourced from two phase 2 randomized trials of MDMA-AT for chronic PTSD, in...

DOI: 10.1177/02698811261464502 (opens in new tab)

Clinical trials

All mdma for ptsd trials →